Resistentia Pharmaceuticals AB Report issue

For profit Phase 2
Founded: Uppsala Sweden (1998)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2007
NCT00439621
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

rp 01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1